arrow
C

Cristina Teixidó

Hospital Clínic de Barcelona
H指数:29
被引数:3,758

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Understanding tumor adaptations and resistance to MET inhibitors in MET-altered non-small cell lung cancer

理解MET突变非小细胞肺癌对MET抑制剂的适应与耐药机制

2026-09-010
PRE
Multicenter evaluation of the Idylla IDH1-2 Mutation Assay Kit for detection of IDH mutational status in glioma

多中心评估Idylla IDH1-2突变检测试剂盒在胶质瘤中检测IDH突变状态的应用

2026-03-130
OAAI
Corrigendum to ”Characterization and economic burden of KRASG12C-mutant lung cancer in real-world Spanish practice: a retrospective observational study (SILK study)” [Lung Cancer 206 (2025) 108677]

勘误:“KRASG12C突变型肺癌在西班牙真实世界实践中的特征和经济负担:一项回顾性观察性研究(SILK研究)”[肺癌 206 (2025) 108677]

2025-10-080
OAAI
Characterization and economic burden of KRASG12C-mutant lung cancer in real-world Spanish practice: a retrospective observational study (SILK study)

KRASG12C突变型肺癌在西班牙真实世界实践中的特征及经济负担:一项回顾性观察性研究(SILK研究)

2025-07-220
PRE
Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)

驱动基因致癌突变在非小细胞肺癌中的频率及欧洲室内氡暴露的估计(RADON EUROPE研究)

2025-06-260
OA
Prevalence and characteristics of lung cancer in families harboring Pathogenic Germline Variants in cancer predisposing genes: A 20-year retrospective analysis

携带癌易感基因致病性胚系变异的家庭中肺癌的患病率及特征:一项20年回顾性分析

2025-06-060
PRE
Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study

西班牙早期可切除非小细胞肺癌患者中EGFR基因突变的发生率:ORIGEN研究

2025-04-010
OA
Brief Report: Real-World Clinical Utility of Next-Generation Sequencing of Circulating Tumor DNA for Patients With Advanced Lung Squamous Cell Carcinoma (SQUIN)

简报:循环肿瘤DNA下一代测序在晚期肺鳞癌患者中的临床实用性(SQUIN)

2025-02-140
PRE
Activity of brigatinib based on genomic alterations detected on ctDNA at baseline and at progression in ALK inhibitor-naive advanced ALK plus NSCLC from the ALTA-1L trial

基于ALTA-1L试验中ALK抑制剂初治晚期ALK阳性NSCLC患者基线和进展时ctDNA检测的基因组改变评估brigatinib的活性

2024-09-010
PRE
RET Fusion Testing in Patients With NSCLC: The RETING Study
2024-04-012
OA
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
2023-12-153
PRE
ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain
2023-10-010
OA